mirvetuximab soravtansine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
chimeric origin 5691 1453084-37-1

Description:

MoleculeDescription

Molfile

Synonyms:

  • mirvetuximab soravtansine
  • mirvetuximab soravtansine-gynx
  • elahere
  • IMGN853
Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate receptor alpha (FRalpha). The small molecule, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRalpha, mirvetuximab soravtansine-gynx is internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death.
  • Molecular weight:
  • Formula: C2H7N(C41H56ClN3O14S3)n
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Nov. 14, 2022 FDA IMMUNOGEN INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 235.62 44.04 33 1216 675 90626523
Keratitis 172.06 44.04 32 1217 3974 90623224
Pneumonitis 120.27 44.04 38 1211 44132 90583066
Disease progression 85.47 44.04 42 1207 156573 90470625
Ocular toxicity 81.98 44.04 14 1235 1063 90626135
Death 78.21 44.04 58 1191 456493 90170705
Neuropathy peripheral 72.49 44.04 36 1213 136934 90490264
Abdominal pain 67.05 44.04 50 1199 395671 90231527
Cataract 60.13 44.04 26 1223 72066 90555132
Vision blurred 58.33 44.04 29 1220 110264 90516934
Thrombocytopenia 48.31 44.04 32 1217 208693 90418505
Punctate keratitis 44.77 44.04 8 1241 788 90626410

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratitis 69.38 55.27 13 489 5131 110583666
Keratopathy 63.91 55.27 10 492 1363 110587434

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX26 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
FRalpha positive platinum-resistant epithelial ovarian cancer indication 254849005
FRalpha positive platinum-resistant fallopian tube cancer indication 363444001 DOID:1964
FRalpha positive platinum-resistant primary peritoneal cancer indication 363492001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Folate receptor alpha Membrane receptor BINDING AGENT Kd 10.12 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:755477 CHEBI
CHEMBL3545132 ChEMBL_ID
C000607289 MESH_SUPPLEMENTAL_RECORD_UI
12250 IUPHAR_LIGAND_ID
DB12489 DRUGBANK_ID
4041843 VANDF
4041844 VANDF
C4288736 UMLSCUI
10176 INN_ID
D10954 KEGG_DRUG
91810695 PUBCHEM_CID
363141 MMSL
41058 MMSL
d09944 MMSL
019225 NDDF
98DE7VN88D UNII
2621548 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ELAHERE HUMAN PRESCRIPTION DRUG LABEL 1 72903-853 INJECTION, SOLUTION 5 mg INTRAVENOUS BLA 33 sections